Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 2, 2018

Edwards Lifesciences secures CE-Mark for Cardioband system

Edwards Lifesciences in the US has secured the European CE-Mark for its Cardioband Tricuspid Valve Reconstruction System designed to treat tricuspid heart valve disease. 

Edwards Lifesciences in the US has secured the European CE-Mark for its Cardioband Tricuspid Valve Reconstruction System designed to treat tricuspid heart valve disease.

Performed through transfemoral route, this transcatheter therapy minimises tricuspid regurgitation through annular reduction.

The system facilitates accurate positioning to the specific anatomy of a patient, along with real-time adjustment and simultaneous confirmation of results.

Edwards Lifesciences transcatheter mitral and tricuspid therapies corporate vice-president Bernard Zovighian said: “We are very pleased to be developing the most comprehensive product portfolio to address both mitral and tricuspid valve disease and to demonstrate continued progress on this robust pipeline of innovative transcatheter therapies for patients in need.

“Although open-heart surgical valve repair is practiced today, it has not been performed frequently for those suffering from tricuspid regurgitation.”

“We are committed to building a significant body of clinical evidence, including the collection of real-world data, on this important new therapy for patients who have few or no other treatment options.”

The European approval is based on the clinical results obtained from TRI-REPAIR CE Mark study, in which the Cardioband System demonstrated potential as a treatment option for tricuspid regurgitation.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

University Hospital Bonn Cardiology department chief Georg Nickenig said: “Although open-heart surgical valve repair is practiced today, it has not been performed frequently for those suffering from tricuspid regurgitation, despite evidence of increased mortality in these patients.

“Now with the European approval of the Cardioband Tricuspid System as the first transcatheter tricuspid therapy, patients can have access to a minimally invasive treatment designed to reduce tricuspid regurgitation and improve their symptoms and quality of life.”

Edwards Lifesciences purchased the Cardioband System from Valtech Cardio in January last year. The CE-Mark triggers a pre-specified milestone payment of about $50m to former Valtech Cardio investors.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU